文献速递胃肠外科围术期管理与 ERAS

荧光淋巴造影对新辅助化疗后胃癌预后的影响

Prognostic Impact of Fluorescent Lymphography on Gastric Cancer After Neoadjuvant Chemotherapy.
PubMed 文献 · JAMA Surg · 2025-01-01

该回顾性队列研究纳入459例接受新辅助化疗后行腹腔镜根治性胃切除术的局部进展期胃癌患者,其中119例接受ICG引导淋巴结清扫。经重叠权重调整后,ICG组收获淋巴结数更多(47.4 vs 38.3,P < .001),3年总生存率(78.6% vs 66.6%,P = .04)和无复发生存率(74.0% vs 57.0%,P = .03)均更优。ICG示踪是OS(HR 0.59,95%CI 0.39-0.90,P = .02)和RFS(HR 0.59,95%CI 0.40-0.87,P = .01)的独立预后因素。

要点

  • ICG引导淋巴结清扫可提高局部进展期胃癌新辅助化疗后淋巴结收获数。
  • ICG示踪与更好的3年OS和RFS相关,且为独立预后因素。
  • ypN2/3及主要病理缓解亚组中ICG的OS获益更明显。

核心结论

  • ICG示踪与新辅助化疗后局部进展期胃癌患者更充分的淋巴结清扫和改善的生存结局相关。
  • 仍需前瞻性随机临床试验验证这些发现。

研究设计与样本

  • 回顾性队列研究,纳入2015年1月至2021年6月中国3家教学医院接受新辅助化疗后腹腔镜根治性胃切除术的cT2-4N0/+M0胃腺癌患者459例。
  • 采用重叠权重比较ICG组与非ICG组,并用倾向性评分匹配和工具变量分析检验稳健性。

主要发现

  • ICG组119例;总体459例中男338例(73.6%),女121例(26.4%),平均年龄60.8(9.9)岁。
  • 重叠权重调整后,ICG组淋巴结收获数47.4 vs 38.3(P < .001)。
  • 3年OS为78.6% vs 66.6%(P = .04),3年RFS为74.0% vs 57.0%(P = .03)。
  • 多变量Cox回归显示ICG示踪为OS独立预后因素(HR 0.59,95%CI 0.39-0.90,P = .02)和RFS独立预后因素(HR 0.59,95%CI 0.40-0.87,P = .01)。
  • 亚组分析中,ypN2/3组OS 70.3% vs 36.2%(P = .01),主要病理缓解组OS 97.7% vs 77.6%(P = .04),交互作用P均为.04。

临床怎么用

  • 对新辅助化疗后局部进展期胃癌行腹腔镜根治性胃切除术时,可考虑ICG引导淋巴结清扫以增加淋巴结收获并可能改善生存。
  • 需结合ypN分期和病理缓解程度评估ICG示踪的潜在获益人群。

局限性

  • 回顾性设计,存在选择偏倚可能。
  • 样本来自3家教学医院,外推性需谨慎。
  • 需前瞻性随机临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Indocyanine green (ICG)-guided lymphadenectomy has been increasingly used to treat gastric cancer. However, its oncologic impact remains unclear. OBJECTIVE: To investigate the effect of ICG tracing on long-term outcomes in patients diagnosed with locally advanced gastric cancer undergoing neoadjuvant chemotherapy (NAC) followed by laparoscopic radical gastrectomy. DESIGN, SETTINGS, AND PARTICIPANTS: This retrospective cohort study included patients diagnosed with cT2-4N0/+M0 gastric adenocarcinoma who underwent NAC and laparoscopic radical gastrectomy at 3 teaching hospitals in China between January 2015 and June 2021, with follow-up data examined until June 2024. Overlap weighting (OW) was used to compare outcomes between the ICG and non-ICG groups. Results were tested for robustness using propensity score matching (PSM) and instrumental variable analysis. EXPOSURE: ICG-guided lymphadenectomy during laparoscopic gastrectomy. MAIN OUTCOMES AND MEASURES: The primary end points were 3-year survival outcomes, including overall survival (OS) and recurrence-free survival (RFS). RESULTS: Data from 459 patients (338 men [73.6%] and 121 women [26.4%]; mean [SD] age, 60.8 [9.9] years), of whom 119 underwent ICG-guided lymphadenectomy, were included. After OW adjustment, the ICG group exhibited a higher number of lymph nodes harvested (47.4 vs 38.3; P < .001) and better 3-year OS (78.6% vs 66.6%; P = .04) and RFS (74.0% vs 57.0%; P = .03) compared with the non-ICG group. Multivariable Cox regression analysis revealed that ICG tracing was an independent prognostic factor for both OS (hazard ratio, 0.59; 95% CI, 0.39-0.90; P = .02) and RFS (hazard ratio, 0.59; 95% CI, 0.40-0.87; P = .01), with the results remaining significant in both doubly robust and instrumental variable-adjusted models. Furthermore, in the OW-adjusted population, the OS benefit of ICG tracing was more pronounced in subgroups with ypN2/3 gastric adenocarcinoma (70.3% vs 36.2%; P = .01) and those achieving major pathological response (97.7% vs 77.6%; P = .04) (both P for interaction = .04). Similar results were obtained after adjusting for PSM. CONCLUSION AND RELEVANCE: In this study, ICG tracing was associated with enhanced lymphadenectomy and improved survival outcomes in patients with locally advanced gastric cancer after NAC. A prospective randomized clinical trial is needed to verify these findings.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Tang YH, Huang ZN, Sun YQ, et al. Prognostic Impact of Fluorescent Lymphography on Gastric Cancer After Neoadjuvant Chemotherapy. JAMA Surg. 2025. PMID: 40072431. doi:10.1001/jamasurg.2025.0108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。